This new strategy overcomes the problems of BRD4 inhibitions, which led to robust BRD4 protein accumulation.1 Later on in 2016, this group confirmed the effect of ARV‐825 in five MM cell lines [SKO‐007(J3), U266, RPMI‐8226, ARP‐1, JJN3] and an MM patient‐arised CD138+ MM cells. This evidence concerns the gene SDC1 and Miyoshi myopathy.